Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: Results from the multicenter FOX study of 177 patients in France

European Journal of Haematology

Volumn 92, Issue 2, 2014, Pages 127-136

  Rey, Jérôme ^a   Viallard, Jean François ^b,g   Keddad, Karim ^c   Smith, Jonathan ^d   Wilde, Paul ^d   Kiladjian, Jean Jacques ^e,f   Abgrall, J F ^g   Adiko, D ^g   Allangba, O ^g   Bakir, R ^g   Besson, C ^g   Bons, J M ^g   Bordessoule, D ^g   Boyer Perrard, F ^g   Cambier, N ^g   Camo, J M ^g   Casadevall, N ^g   Christian, B ^g   Cony Makhoul, P ^g   De Faucal, P ^g   De Jaureguiberry, J P ^g   Demory, J L ^g   Dine, G ^g   Espinouse, D ^g   Feugier, P ^g   Fezoui, H ^g   Fitoussi, O ^g   Frenkiel, N ^g   Genereau, T ^g   Guyotat, D ^g   Hacini, M ^g   Hutin, P ^g   Ianotto, J C ^g   Kiladjian, J J ^g   Lionne, P ^g   Liu, V ^g   Maloisel, F ^g   Ojeda Uribe, M ^g   Orfeuvre, H ^g   Pautas Chambon, C ^g   Pignon, B ^g   Rodon, P ^g   Rosenthal, E ^g   Sanhes, L ^g   Sebahoun, G ^g   Thioliere, B ^g   Wattel, E ^g   more..

^a INSTITUT PAOLI CALMETTES   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c Medtronic France SAS   (France)

^d Shire Pharmaceuticals   (United Kingdom)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g NONE

Author keywords

Anagrelide; Blood platelets; Essential thrombocythemia; Hydroxycarbamide; Intolerance; Myeloproliferative disorders; Platelet count; Resistance; Switch

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; PEGINTERFERON ALPHA2A; PIPOBROMAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; CEREBROVASCULAR ACCIDENT; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FRANCE; HEADACHE; HEART FAILURE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERTENSIVE CRISIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RASH; RECOMMENDED DRUG DOSE; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TINNITUS; VEIN THROMBOSIS; VERTIGO; VERY ELDERLY;

ANAGRELIDE; BLOOD PLATELETS; ESSENTIAL THROMBOCYTHEMIA; HYDROXYCARBAMIDE; INTOLERANCE; MYELOPROLIFERATIVE DISORDERS; PLATELET COUNT; RESISTANCE; SWITCH;

ADULT; AGED; AGED, 80 AND OVER; DRUG SUBSTITUTION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; QUINAZOLINES; RETREATMENT; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892669231     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12210     Document Type: Article

References (15)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press, 2008.
2. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:171-3.
3. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-82.
4. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70.
5. European Medicines Agency. Xagrid Summary of Product Characteristics. Last update 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000480/WC500056557.pdf. Accessed May 7, 2013.
6. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
7. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999;29:29-35.
8. Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ, Hasselbalch HC. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004;26:335-40.
9. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, Gisslinger H. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-46.
10. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-8.
11. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
12. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
13. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113:4829-33.
14. Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Abhyankar B, Birgegard G. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res 2013;37:162-8.
15. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-91.